James Nie

James Nie

Auto-generated profile, based on publicly available information

James Nie

Department of Urology, Yale University School of Medicine, New Haven, Connecticut

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2020 in Cells
Verified
Journal Article
Open access
PDF file
Biraja DashBiraja Dash
Biraja Dash
OSOcean Setia
Ocean Setia
JGJolanta Gorecka
Jolanta Gorecka
HPHassan Peyvandi
Hassan Peyvandi
KDKaiti Duan
Kaiti Duan
HHHenry Hsia
Henry Hsia
The application of human-induced pluripotent stem cells (hiPSCs) to generate vascular smooth muscle cells (hiPSC-VSMCs) in abundance is a promising strategy for vascular regeneration. While hiPSC-VSMCs have already been utilized for tissue-engineered vascular grafts and disease modeling, there is a lack of investigations exploring their therapeutic secretory factors. The objective of this manuscript was to understand how the biophysical property of a collagen-based scaffold dictates changes in the secretory function of hiPSC-VSMCs while developing hiPSC-VSMC-based therapy for durable regenerative wound healing. We investigated the effect of collagen fibrillar density (CFD) on hiPSC-VSMC’s paracrine secretion and cytokines via the construction of varying density of collagen scaffolds. Our study demonstrated that CFD is a key scaffold property that modulates the secretory function of hiPSC-VSMCs. This study lays the foundation for developing collagen-based scaffold materials for the delivery of hiPSC-VSMCs to promote regenerative healing through guiding paracrine signaling pathways.

1 January 2022 in Urology Practice
Verified
Journal Article
Closed access
JNJames Nie
James Nie
PDPatrick C. Demkowicz
Patrick C. Demkowicz
WHWalter Hsiang
Walter Hsiang
WUWaez Umer
Waez Umer
ECEvan M. Chen
Evan M. Chen
MLMichael S. Leapman
Michael S. Leapman
Introduction:Private equity firms have recently acquired several large urology practices in the United States. As little is known about these acquisitions, we sought to characterize trends ...

1 July 2022 in Surgery
Verified
Journal Article
Closed access
STSina J. Torabi
Sina J. Torabi
RPRahul A. Patel
Rahul A. Patel
JBJack Birkenbeuel
Jack Birkenbeuel
JNJames Nie
James Nie
DKDavid A. Kasle
David A. Kasle
RMR. Peter Manes
R. Peter Manes

2 November 2023 in JMIR Cancer
Verified
Journal Article
Open access
VMVictoria A Marks
Victoria A Marks
WHWalter R Hsiang
Walter R Hsiang
JNJames Nie
James Nie
WUWaez Umer
Waez Umer
AHAfash Haleem
Afash Haleem
MLMichael S Leapman
Michael S Leapman
Background: Telehealth was an important strategy for maintaining continuity of cancer care during the coronavirus pandemic and has continued to play a role in outpatient care; however, it is unknown whether services are equally available across cancer hospitals. Objective: This study aimed to assess telehealth availability at cancer hospitals for new and established patients with common cancers to contextualize the impact of access barriers to technology on overall access to health care. Methods: We conducted a national cross-sectional secret shopper study from June to November 2020 to assess telehealth availability at cancer hospitals for new and established patients with colorectal, breast, and skin (melanoma) cancer. We examined facility-level factors to determine predictors of telehealth availability. Results: Of the 312 investigated facilities, 97.1% (n=303) provided telehealth services for at least 1 cancer site. Telehealth was less available to new compared to established patients (n=226, 72% vs n=301, 97.1%). The surveyed cancer hospitals more commonly offered telehealth visits for breast cancer care (n=266, 85%) and provided lower access to telehealth for skin (melanoma) cancer care (n=231, 74%). Most hospitals (n=163, 52%) offered telehealth for all 3 cancer types. Telehealth availability was weakly correlated across cancer types within a given facility for new (r=0.16, 95% CI 0.09-0.23) and established (r=0.14, 95% CI 0.08-0.21) patients. Telehealth was more commonly available for new patients at National Cancer Institute–designated facilities, medical school–affiliated facilities, and major teaching sites, with high total admissions and below-average timeliness of care. Telehealth availability for established patients was highest at Academic Comprehensive Cancer Programs, nongovernment and nonprofit facilities, medical school–affiliated facilities, Accountable Care Organizations, and facilities with a high number of total admissions. Conclusions: Despite an increase in telehealth services for patients with cancer during the COVID-19 pandemic, we identified differences in access across cancer hospitals, which may relate to measures of clinical volume, affiliation, and infrastructure.

23 March 2020 in The Clinical Teacher
Verified
Journal Article
Closed access
PDF file
JNJames Nie
James Nie
STSina Torabi
Sina Torabi
CPConnor Peck
Connor Peck
HNHalsey Niles
Halsey Niles
JEJohn Encandela
John Encandela